#Merck

A personalized melanoma vaccine enters a Phase III study, while a pancreatic cancer vaccine moves on to Phase II.

Moderna and Merck’s customized neoantigen vaccine plus Keytruda lowered the risk for metastasis or death by 65%.

Since 2020, there has been a nationwide shortage of the bladder cancer therapy Bacillus Calmette Guérin (BCG). Here’s why.

A personalized cancer vaccine plus Keytuda lowered the risk of melanoma coming back after surgery.

Keytruda can activate T cells that harbor latent HIV, a possible step toward a functional cure.

Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.

Another vaccine, from Novavax, was 89% effective in a U.K. trial, but both were less potent against the South African coronavirus mutation.

Keytruda plus chemotherapy reduced the risk of disease progression or death by 35% compared with chemotherapy alone in certain people.

Couric has partnered with Merck to produce a web series about being treated for cancer during the pandemic.

The American Red Cross and the American Cancer Society come together to encourage people to #GiveBloodtoGiveTime.

Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.

Adding immunotherapy to preoperative chemotherapy increased the likelihood of complete remission.

New immunotherapy option approved for uncommon, aggressive type of lung cancer.

First-line immunotherapy improved overall survival by around 20% to 40%, depending on PD-L1 level.

The immunotherapy led to an improvement in survival for people with gastric or gastroesophageal junction cancers with a high PD-L1 level.

The immunotherapy drug shows the most benefit for newly treated people with tumors that test positive for the PD-L1 biomarker.